CHANGES IN PHARMACOLOGICAL TREATMENT PATTERN FOR TYPE 2 DIABETES IN FIVE YEARS: BEFORE AND AFTER THE INTRODUCTION OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITOR AT A DIABETES SPECIALIST CLINIC IN TOKYO

被引：0
|
作者：
Watanabe, Y. [1 ]
Takayama, C. [2 ]
Asada, Y. [2 ]
Mori, T. [2 ]
Kawagoe, Y. [1 ]
Fujii, H. [1 ]
Miyakawa, T. [1 ]
机构：
[1] Tama Ctr Mirai Clin, Internal Med, Tokyo, Japan
[2] Yamato Prescript Ctr, Tokyo, Japan
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2014年 / 106卷
关键词：
D O I：
10.1016/S0168-8227(14)70492-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO198
引用
收藏
页码：S148 / S149
页数：2
相关论文
共 50 条
  • [31] Linagliptin: The Newest Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Mellitus
    Aletti, Rachael
    Cheng-Lai, Angela
    CARDIOLOGY IN REVIEW, 2012, 20 (01) : 45 - 51
  • [32] Transitioning from insulin to dipeptidyl-peptidase 4 (DPP-4) inhibitors for type 2 diabetes
    Hamrick, Irene
    Goblirsch, Matthew Joseph
    Tuan, Wen-Jan
    Beckham, Felicia
    GERIATRIC NURSING, 2022, 46 : 86 - 89
  • [33] Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
    Kishimoto, Miyako
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2013, 6 : 187 - 195
  • [34] Alogliptin: A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Mellitus
    Jarvis, Courtney I.
    Cabrera, Adriana
    Charron, Derek
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (11) : 1532 - 1539
  • [35] Serum Level of Soluble CD26/DPP-4 Predicts the Response to Sitagliptin, a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, in Patients With Type 2 Diabetes Inadequately Controlled by Metformin and/or Sulfonylurea
    Aso, Yoshimasa
    Inukai, Toshihiko
    Kasai, Kikuo
    DIABETES, 2012, 61 : A240 - A240
  • [36] Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea
    Aso, Yoshimasa
    Ozeki, Noriyuki
    Terasawa, Tomoko
    Naruse, Rika
    Hara, Kenji
    Suetsugu, Mariko
    Takebayashi, Kohzo
    Shibazaki, Mitsuei
    Haruki, Kohsuke
    Morita, Kimio
    Inukai, Toshihiko
    TRANSLATIONAL RESEARCH, 2012, 159 (01) : 25 - 31
  • [37] Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
    Pratley, Richard E.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (03) : 503 - 512
  • [38] Dipeptidyl peptidase-4 inhibitor treatment could decreaseKlebsiella pneumoniaepneumonia in patients with type 2 diabetes
    Chen, Hsin-Hung
    Chen, Ching-Chu
    Ho, Chun-Wei
    Hsieh, Ming-Chia
    Hsu, Sheng-Pang
    Lin, Cheng-Li
    Kao, Chia-Hung
    POSTGRADUATE MEDICINE, 2020, 132 (08) : 714 - 719
  • [39] A dipeptidyl peptidase-4 (DPP-4) inhibitor suppresses foam cell formation of macrophages through the suppresion of CD36 in type 1 diabetes
    Terasaki, M.
    Yashima, H.
    Mori, Y.
    Saito, T.
    Hiromura, M.
    Kushima, H.
    Koshibu, M.
    Osaka, N.
    Ohara, M.
    Fukui, T.
    Hirano, T.
    Yamagishi, S. -I.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S438 - S438
  • [40] Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin
    Herman, G. A.
    Stein, P. P.
    Thornberry, N. A.
    Wagner, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) : 761 - 767
12345